Close Menu

NEW YORK (GenomeWeb) – Cancer informatics and precision medicine firm Tempus said today that it has raised $110 million in a Series E financing round.

Participants in the round included Baillie Gifford, funds and accounts managed by T. Rowe Price, Revolution Growth, New Enterprise Associates, and other existing investors.

Tempus, based in Chicago, said that it will use the additional funds to grow operations and expand into new therapeutic areas and geographies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.